Astrazeneca

AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Type
Public
HQ
London, GB
Founded
1999
Employees
61,500 (est)+7%

Key People at Astrazeneca

Mark Mallon

Mark Mallon

Executive Vice President, International
Caroline Hempstead

Caroline Hempstead

Executive Vice President, Human Resources and Corporate Affairs (interim)
Marc Dunoyer

Marc Dunoyer

Executive Director, Chief Financial Officer
Linda C. Bain

Linda C. Bain

USA/Canada Head - Global R&D Finance
Ed Mathers

Ed Mathers

Team Member
Katarina Ageborg

Katarina Ageborg

Chief Compliance Officer
Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Marc Dunoyer

Marc Dunoyer

Executive Director and Chief Financial Officer
Menelas Pangalos

Menelas Pangalos

Executive Vice President
Bahija Jallal

Bahija Jallal

Executive Vice President
Luke Miels

Luke Miels

Executive Vice President Global Product and Portfolio Strategy
Paul Hudson

Paul Hudson

President, AstraZeneca US and Executive Vice President
Ruud Dobber

Ruud Dobber

Executive Vice President
Mark Mallon

Mark Mallon

Executive Vice President
Fiona Cicconi

Fiona Cicconi

Executive Vice President
Katarina Ageborg

Katarina Ageborg

Chief Compliance Officer
Jeff Pott

Jeff Pott

General Counsel
Pam Cheng

Pam Cheng

Executive Vice-President

Astrazeneca Locations

London, GB
Denver, US
Bangalore, IN
New Brunswick, US
Wilmington, US
Cincinnati, US
Roanoke, US
Hong Kong, HK
Shanghai, CN
Osaka, JP
Jackson, US
Wedel, DE
Derby, GB
Toledo, US
Gaithersburg, US
Dallas, US
Leiden, NL
Los Angeles, US
Albany, US
Durham, US

Astrazeneca Metrics

Astrazeneca Summary

Founding Date

1999

Market capitalization

$65.5 B

Closing share price

$25.8

Astrazeneca Financials

FY, 2013FY, 2014FY, 2015

Revenue

£16.9 B£19.6 B£18.3 B

Revenue growth, %

16.1%-6.9%

Cost of sales

£3.46 B£4.32 B£3.44 B

Gross profit

£13.4 B£15.3 B£14.8 B

Gross profit Margin, %

79.5%78.0%81.2%

Operating expense total

£11 B£13.7 B£11.8 B

Astrazeneca Market Value History

Astrazeneca Online Presence

Astrazeneca News

Astrazeneca Company Life

You may also be interested in